Boston Scientific warns of tough 2027 on China pricing, heart-device weakness

By Padmanabhan Ananthan Oct 28 (Reuters) Boston Scientific lowered its full-year profit forecast on Wednesday and warned that revenue and earnings growth could be challenging in 2027, ​citing pricing pressure in China and weakness in ‌its key heart-device businesses. Shares of the company were down 5.3% by afternoon. We anticipate continued top-line pressure into 2027, which we expect will make it challenging to grow revenue and adjusted earnings per share, CFO ‌Jon ​Monson said in a conference call. The ⁠medtech company now expects ⁠2026 adjusted profit in the range of $3.16 to $3.18, compared with a previous range of $3.28 to $3.32. Analysts on average expect earnings of $3.23 per share, according to data compiled by ​LSEG. The company expects fourth-quarter sales to fall about 3% to 1% year over year and adjusted earnings of ⁠77 to 79 cents per share, ⁠below analysts estimate of 83 cents per ​share. Chief Executive Mike Mahoney said, there will be additional price headwinds ​i